| Determining cell type abundance and expression from bulk tissues with digital cytometry AM Newman, CB Steen, CL Liu, AJ Gentles, AA Chaudhuri, F Scherer, ... Nature biotechnology 37 (7), 773-782, 2019 | 3073 | 2019 |
| Integrated digital error suppression for improved detection of circulating tumor DNA AM Newman*, AF Lovejoy*, DM Klass* (Co-First), DM Kurtz, JJ Chabon, ... Nature biotechnology 34 (5), 547-555, 2016 | 1137 | 2016 |
| Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling AA Chaudhuri, JJ Chabon, AF Lovejoy, AM Newman, H Stehr, TD Azad, ... Cancer discovery 7 (12), 1394-1403, 2017 | 859 | 2017 |
| Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients JJ Chabon*, AD Simmons* (Co-First), AF Lovejoy, MS Esfahani, ... Nature communications 7 (1), 1-15, 2016 | 651 | 2016 |
| Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA F Scherer*, DM Kurtz*, AM Newman* (Co-First), H Stehr, AFM Craig, ... Science translational medicine 8 (364), 364ra155-364ra155, 2016 | 462 | 2016 |
| Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma DM Kurtz*, F Scherer* (Co-First), MC Jin, J Soo, AFM Craig, MS Esfahani, ... Journal of Clinical Oncology 36 (28), 2845, 2018 | 431 | 2018 |
| Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing DM Kurtz*, MR Green* (Co-First), SV Bratman, F Scherer, CL Liu, ... Blood, The Journal of the American Society of Hematology 125 (24), 3679-3687, 2015 | 360 | 2015 |
| Spatially resolved multi-omics deciphers bidirectional tumor-host interdependence in glioblastoma VM Ravi, P Will, J Kueckelhaus, N Sun, K Joseph, H Salié, L Vollmer, ... Cancer cell 40 (6), 639-655. e13, 2022 | 272 | 2022 |
| Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA DM Kurtz, J Soo, L Co Ting Keh, S Alig, JJ Chabon, BJ Sworder, A Schultz, ... Nature biotechnology 39 (12), 1537-1547, 2021 | 220 | 2021 |
| Dynamic risk profiling using serial tumor biomarkers for personalized outcome prediction DM Kurtz*, MS Esfahani*, F Scherer* (Co-First), J Soo, MC Jin, CL Liu, ... Cell 178 (3), 699-713. e19, 2019 | 187 | 2019 |
| T-cell dysfunction in the glioblastoma microenvironment is mediated by myeloid cells releasing interleukin-10 VM Ravi, N Neidert, P Will, K Joseph, JP Maier, J Kückelhaus, L Vollmer, ... Nature communications 13 (1), 925, 2022 | 186 | 2022 |
| Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discov. 2017; 7: 1394–1403. doi: 10.1158/2159-8290 AA Chaudhuri, JJ Chabon, AF Lovejoy, AM Newman, H Stehr, TD Azad, ... CD-17-0716.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 86 | |
| High-throughput sequencing for noninvasive disease detection in hematologic malignancies F Scherer*, DM Kurtz* (Co-First), M Diehn, AA Alizadeh Blood 130 (4), 440-452, 2017 | 82 | 2017 |
| Comparative genomics reveals multistep pathogenesis of E2A-PBX1 acute lymphoblastic leukemia J Duque-Afonso, J Feng, F Scherer, CH Lin, SHK Wong, Z Wang, ... The Journal of Clinical Investigation 125 (9), 3667-3680, 2015 | 77 | 2015 |
| Circulating tumor DNA profiling for detection, risk stratification, and classification of brain lymphomas JA Mutter, SK Alig, MS Esfahani, EM Lauer, J Mitschke, DM Kurtz, J Kühn, ... Journal of Clinical Oncology 41 (9), 1684-1694, 2023 | 64 | 2023 |
| Early assessment of circulating tumor DNA after curative‐intent resection predicts tumor recurrence in early‐stage and locally advanced non‐small‐cell lung cancer S Waldeck, J Mitschke, S Wiesemann, M Rassner, G Andrieux, M Deuter, ... Molecular oncology 16 (2), 527-537, 2022 | 60 | 2022 |
| Organocatalytic removal of formaldehyde adducts from RNA and DNA bases S Karmakar, EM Harcourt, DS Hewings, F Scherer, AF Lovejoy, DM Kurtz, ... Nature chemistry 7 (9), 752-758, 2015 | 58 | 2015 |
| Short diagnosis-to-treatment interval is associated with higher circulating tumor DNA levels in diffuse large B-cell lymphoma S Alig, CW Macaulay, DM Kurtz, U Dührsen, A Hüttmann, C Schmitz, ... Journal of Clinical Oncology 39 (23), 2605-2616, 2021 | 54 | 2021 |
| Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discov. 2017; 7 (12): 1394–403 AA Chaudhuri, JJ Chabon, AF Lovejoy, AM Newman, H Stehr, TD Azad, ... doi. org/10.1158/2159-8290. Cd-17-0716, 2017 | 50 | 2017 |
| Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research EM Lauer, J Mutter, F Scherer Leukemia 36 (9), 2151-2164, 2022 | 48 | 2022 |
Ash A. Alizadeh, MD, PhDStanford University, Moghadam Family Professor of MedicineEmail verificata su stanford.edu
